Pharmaceutical Industry in the
Canton of Valais
53 companies in Pharmaceutical Industry based in the Canton of Valais — name and year of registration from the commercial register.
50 of 53 companies
Naturalpes Pharma SA
Since 2023 · 1–10 empl.4.9(258)
Naturalpes Pharma SA sells CBD products through an e-commerce platform and physical stores, offering oils, cosmetics, teas, CBD flowers, resins and pet formulations. The company provides laboratory analyses, batch traceability and quality controls, and states certifications such as B Corp and ISO standards.
PharmAlp SA
Since 2011 · 11–20 empl.4.9(10)
The core activity of Pharmalp is the development and manufacture of health products, particularly dietary supplements and medicines based on natural ingredients, used to support health and prevent diseases.
Valsynthese SA
Since 1983 · 101–500 empl.5.0(4)
The core activity of Valsynthese SA consists in the development and manufacture of chemical derivatives, in particular nitrite, nitro, carboxylic acid, anhydride and amino acid derivatives, as well as other specialized chemical products. The company offers custom manufacturing services, where it supports customers in the development and production of specific chemical products.
Debiopharm Research & Manufacturing SA
Since 1988 · 101–500 empl.4.3(4)
Debiopharm Research & Manufacturing SA is a pharmaceutical research, development and production facility inspected and registered with major regulatory authorities. It develops and manufactures PLGA-based injectable sustained‑release formulations (1‑, 3‑ and 6‑month releases) and pursues nanoparticulate drug‑delivery systems.
Excellgene SA
Since 2004 · 11–20 empl.5.0(1)
ExcellGene is a Swiss Biologics-CDMO (Contract Development and Manufacturing Organization) specialized in the development and manufacturing of proteins for the pharmaceutical industry. The company's core activity encompasses providing services for the development and manufacturing of biologics, including: cell line development (CHO and HEK cells), genome engineering, cGMP cell banking, process development, ensuring clonality of existing cell lines, and biosimilars. The company supports pharmaceutical companies in the development and manufacturing of proteins for drug development, offering a combination of scientific expertise and technological infrastructure.
TRB CHEMEDICA SA
Since 1964 · 101–500 empl.4.2(11)
The core activity of TRB Chemedica International SA is the development, manufacture and marketing of medical products based on hyaluronic acid, particularly for the therapeutic areas of ophthalmology, rheumatology and neurology. The products include, among others, eye care products, injections for the treatment of joint pain and tendon diseases, as well as products for arthroscopy.
Siegfried Evionnaz SA
Since 2015 · 101–500 empl.3.8(13)
Siegfried Evionnaz SA is a pharmaceutical production and development site specializing in custom synthesis and development of active pharmaceutical ingredients (APIs) and intermediates. The site provides chemical process R&D and analytical development services with capacity ranging from gram-scale to industrial production.
BioAtrium AG
Since 2017 · 101–500 empl.4.8(4)
BioAtrium AG is a joint venture between Lonza and Sanofi. The company’s purpose is the construction, ownership and operation of a biopharmaceutical mammalian cell-culture production facility and the development, manufacture and supply of biopharmaceutical cell-culture products.
Bachem SA, succursale de Vionnaz
Since 2011 · 101–500 empl.4.5(4)
Bachem SA, succursale de Vionnaz is a contract development and manufacturing organization (CDMO) specializing in the development and manufacture of peptides and oligonucleotides. It supplies products for research, clinical development and commercial application and provides services including CMC development, GMP production, analytical testing and custom synthesis.
IHMA Europe Sàrl
Since 2009 · 21–50 empl.5.0(1)
The core activity of International Health Management Associates (IHMA) is to support pharmaceutical companies in the development of medicines, particularly in the area of antimicrobial therapies. IHMA offers a wide range of services, including: * Drug Discovery: Identification and development of new medicines * Clinical Development: Conducting clinical trials and tests * Regulatory Submissions: Supporting the approval of medicines by regulatory authorities * Commercialization: Supporting the market launch and marketing of medicines IHMA has its own laboratories and uses modern technologies to deliver high-quality tests and data. The company works closely with healthcare institutions and pharmaceutical companies to enable successful drug developments.
Phytocon GmbH
Since 1997 · 1–10 empl.
Phytocon develops and distributes vegan natural cosmetics and dietary supplements based on natural ingredients, aiming to sustainably care for and protect the skin and body. The products are designed to stimulate the body's self-healing powers and support biological regeneration processes of the skin.
Straqim SA
Since 2001 · 21–50 empl.
Straqim SA is a Swiss company that distributes bulk active pharmaceutical ingredients (APIs) and develops, registers and commercializes proprietary consumer health ingredients. The company sources APIs through exclusive distribution agreements, manages international supply chains and markets branded consumer health products such as Algalithe, Immunea, Oselan, Prunus4Life and Reginator.
BAXTER Group AG
Since 2009 · 21–50 empl.
BAXTER Group AG is a healthcare company that supplies medical devices, injectable medicines and clinical nutrition products for hospital, renal and surgical care.
Phi Pharma SA
Since 2011 · 11–20 empl.
The company's core activity is the development and marketing of therapies for the treatment of cancer.
INFLAMALPS SA
Since 2012 · 11–20 empl.
The core activity of Inflamalps SA is the development of biopharmaceutical products, particularly the discovery and development of anti-inflammatory and anti-microbial molecules for the treatment of diseases, such as dry eye in ophthalmology.
BE-CEUTICALS SA
Since 2013 · 11–20 empl.
The core activity of Be Ceuticals is the development, manufacture and distribution of dermal fillers and skinbooster serums, in particular based on hyaluronic acid, for skin rejuvenation and care.
Swiss Biotech Center SA
Since 2016 · 11–20 empl.
The core activity of Swiss Biotech Center is the development and manufacture of biopharmaceutical products, in particular biological medicines, as well as supporting start-ups and companies in the development and marketing of biopharmaceutical products. The company offers services such as research and development, clinical development, manufacturing and marketing of biopharmaceutical products and has an extensive network and expertise in the biotechnology industry.
Celluris AG
Since 2016 · 21–50 empl.
The core activity of Celluris is the development and research of personalized cancer treatments through CAR-T immunotherapy, specifically the modification of patient cells to recognize and combat tumors.
Straqim Holding SA
Since 2018 · 11–20 empl.
Straqim Holding SA distributes bulk active pharmaceutical ingredients (APIs) and provides contract manufacturing, sourcing and international supply services for pharmaceutical substances. The company also develops, registers and commercializes ingredients for the consumer health market.
Swiss Health Medical Sàrl
Since 2019 · 21–50 empl.
Swiss Health Medical Sàrl operates an online shop offering dietary supplements and health products from the Vita range, including collagen, omega and protein formulations as well as products for joints, immune support and weight management.
CeiROx Life Sciences SA
Since 2007 · 1–10 empl.
CeiROx Life Sciences SA is a company active in the life sciences sector. The website provides only contact details and does not describe specific products or services.
BioXpress Therapeutics SA
Since 2008 · 11–20 empl.
The core activity of BioXpress Therapeutics SA is the development and manufacturing of biosimilars, in particular monoclonal antibodies (mAb), as well as other biological medicines, including gene therapy and cell therapy candidates. The company focuses on developing high-quality, sustainably manufactured biosimilars that aim to improve access to life-saving treatments and reduce healthcare costs.
ImmunSkills SA
Since 2022 · 11–20 empl.
ImmunSkills SA develops allogenic cell‑based therapies for solid cancers, aiming to create a product using allogenic cells that can kill various cancer cells and modify the tumour microenvironment to reduce treatment resistance.
ten23 health Valais AG
Since 2013 · 51–100 empl.3.7(11)
ten23 health Valais AG is a CDMO serving the pharmaceutical industry and biotech start-ups. The company provides pharmaceutical product development, sterile drug manufacturing (fill and finish), and analytical testing and quality control services.
Stämm Vegh SA
Since 2023 · 1–10 empl.
Stämm Vegh SA develops solutions for biomanufacturing, bioengineering and bio‑AI to support biologics and cell therapy production and cell line development. Its offerings include a plug‑and‑play continuous bioreactor (the Bioprocessor) with a bubble‑free bioreactor, automated cell‑line engineering and clone‑selection platforms, and MoNA™ — a transomics platform for multi‑omic analysis and in‑silico cell simulation.
Ceres Heilmittel AG
Since 2011 · 1–10 empl.5.0(1)
Ceres Heilmittel AG produces herbal mother tinctures and liquid plant-based medicinal products and markets a compact natural skincare line. The company processes hand-picked organic and biodynamic medicinal plants using a patented mortar mill, matures extracts over time, and operates an academy for health professionals.
Orio Therapeutics SA
Since 2023 · 1–10 empl.
Orio Therapeutics' core activity is the development of protein-based therapeutics for regenerative medicine, particularly for the treatment of heart attacks. The company focuses on modifying therapeutic proteins to control their localization and delivery, thereby improving efficacy and reducing dosing.
ExcellGene Group SA
Since 2025 · 1–10 empl.
ExcellGene Group SA is a Swiss biologics development company focused on mammalian cell protein expression and bioprocess development. The company supports projects from discovery through development to manufacturing and offers platforms, cell lines, and process and analytical development services.
NUTRICRAFT SA
Since 2025 · 21–50 empl.5.0(1)
NUTRICRAFT SA is a production laboratory specializing in the development and contract manufacture of dietary supplements and nutraceutical products. The company provides formulation and sourcing, capsule/tablet/liquid production, packaging and repackaging, quality control including microbiological analyses, logistics and storage, research and development, and label/marketing services.
Mon Labo SA
Since 2026 · 1–10 empl.
Mon Labo SA is an independent pharmacy specializing in complementary medicine, including aromatherapy, phytotherapy and homeopathy. It also operates in-house laboratories for homeopathic and other custom preparations, and offers a range of house-made products.
Mélane Consulting GmbH
Since 2025 · 1–10 empl.
Mélane Consulting GmbH is a Swiss consulting firm focused on CSV and CQV services for the pharmaceutical and biotechnology sectors. The company supports clients with computer system validation, AI/ML and cloud validation, commissioning, qualification and validation, as well as regulatory support and audit readiness.
Lonza AG
101–500 empl.
Lonza AG is a contract development and manufacturing company serving the healthcare industry. It provides integrated services for biologics, small molecules, bioconjugates, and specialized modalities such as cell and gene therapies, mRNA, and microbial processes.
Homeolab SA
Since 1995 · 1–10 empl.
DSM Nutritional Products AG Zweigniederlassung Werk Lalden
Since 2004 · 1–10 empl.
SILDERMA SARL
Since 2007 · 1–10 empl.
Omnipharm SA
Since 2012 · 1–10 empl.
Kahn Partners Equity Sàrl
Since 2014 · 1–10 empl.
Xcential Sàrl
Since 2015 · 1–10 empl.
Caravella Biopharma SA
Since 2016 · 1–10 empl.
Sacoda PharmConsult GmbH
Since 2017 · 1–10 empl.
EVOLEINA RHODIOLA Sàrl
Since 2019 · 1–10 empl.
Kodiak Sciences Valais GmbH
Since 2020 · 1–10 empl.
IBEX Therapeutics SA
Since 2021 · 1–10 empl.
Leander Hertli Consulting
Since 2022 · 1–10 empl.
Platinum Solutions Sàrl
Since 2023 · 1–10 empl.
Precise Health SA
Since 2023 · 1–10 empl.
CorLinker Biotech GmbH
Since 2024 · 1–10 empl.
Pro Sanitate SA
Since 2024 · 1–10 empl.
Catherine Dieudonné Tivollier TPH PARTNER
Since 2025 · 1–10 empl.
BernaVax Biotech AG
Since 2025 · 1–10 empl.
Pharmaceutical Industry in the Canton of Valais
Pharmaceutical Industry in other places
By canton